Patients with both colorectal ACF and resectable polyps
Conditions
Interventions
receive Montelukast 10mg for 8 weeks
no treatment observation
Sponsors
Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with resectable polyps. 2.Patients with more than 5 rectal ACF 3.Willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: 1.Patients with lesion which preferred early resection. 2.History of use of LTRA within 2months before trial entry. 3.History of malignant disease within 5 yeears before trial entry. 4.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure 5.History of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer and inflammatory bowel disease 6.Pregnancy or possibility of pregnancy 7.Contraindication to Montelukast 8.Allergy to Montelukast 9.Regular use of NSAIDs, metformin, piogrlitazone 10.Patients judged as inappropriate candidates for the trial by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of change rectal ACF in LTRA group and control group after 8weeks intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of rectal ACF before and after intervention in both group Ki67 labeling index of colorectal adnoema/cancer and normal mucosa before and after intervention Safety | — |
Countries
Japan
Contacts
Public ContactTakuma Higurashi
Yokohama City University Department of Gastroenterology and Hepatology
Outcome results
None listed